A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.

Also called NCT05432167

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 195 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
  • Parexel Registry lists this organization as a collaborator
Registry
  • NCT NCT05432167
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05432167. Randomized; double masking; primary purpose treatment. Start 2022-04-29 (actual); primary completion 2024-05-02 (actual). Results posted on 2025-05-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Condition
Uncontrolled Hypertension
Condition
Chronic Kidney Diseases
Intervention (Drug)
CIN-107
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Parexel (class: industry)

Record details

Record id
cardio:ct-nct05432167
Content hash
cccdaf52c562a797887a269710bd315f22b638b66fcef1b871df0af47655a63a